Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study

Abstract Background We conducted a phase II study of carboplatin plus nab‐paclitaxel for the treatment of small cell lung cancer (SCLC) after the failure of a prior standard chemotherapy containing platinum, etoposide, irinotecan, and amrubicin if indicated. Patients with interstitial pneumonia comp...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Naoya Ikeda, Ryo Arai, Sayo Soda, Takashi Inoue, Nobuhiko Uchida, Yusuke Nakamura, Meitetsu Masawa, Yoshitomo Kushima, Hiroaki Okutomi, Akihiro Takemasa, Yasuo Shimizu, Seiji Niho
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2022-05-01
Edice:	Thoracic Cancer
Témata:	carboplatin interstitial pneumonia nab‐paclitaxel small cell lung cancer
On-line přístup:	https://doi.org/10.1111/1759-7714.14394
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!